Title:
TREATMENT OF CHRONIC HEPATITIS B BASED ON INTERFERON SYNERGISTIC IMMUNE CHECKPOINT BLOCKING ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2024/067785
Kind Code:
A1
Abstract:
Provided is use for the treatment of chronic hepatitis B based on an interferon synergistic immune checkpoint blocking antibody. Specifically, provided is a fusion protein, comprising a PDL1-binding polypeptide and an interferon IFN which are operably linked. The fusion protein is a heterodimer protein or a homodimer protein. The fusion protein can achieve the antiviral and immunoregulatory effects of IFN locally in the liver by means of intravenous injection, thereby improving the effectiveness, and reducing side effects.
Inventors:
PENG HUA (CN)
FU YANGXIN (CN)
MENG CHAOYANG (CN)
FU YANGXIN (CN)
MENG CHAOYANG (CN)
Application Number:
PCT/CN2023/122466
Publication Date:
April 04, 2024
Filing Date:
September 28, 2023
Export Citation:
Assignee:
INST BIOPHYSICS CAS (CN)
International Classes:
C07K19/00; A61K38/21; A61K39/395; A61P31/20; C07K14/715; C07K16/28
Domestic Patent References:
| WO2022015711A1 | 2022-01-20 | |||
| WO2020048454A1 | 2020-03-12 |
Foreign References:
| CN108727504A | 2018-11-02 | |||
| CN113876938A | 2022-01-04 | |||
| US20210198375A1 | 2021-07-01 |
Other References:
YONG WU: "Development of monoclonal antibodies against PD-L1 and preliminary investigation on potential application in treatment of chronic hepatitis B virus infection", ZHONGGUO MIANYIXUE ZAZHI = CHINESE JOURNAL OF IMMUNOLOGY, JILIN SHENG YIXUE QIKANSHE, CN, vol. 32, no. 7, 1 January 2016 (2016-01-01), CN , pages 1004 - 1008, XP093153190, ISSN: 1000-484X, DOI: 10.3969/j.issn.1000-484X.2016.07.016
JIAO LIU: " Research Progress of PD-1/PD-L1 Signal Pathway in Immunoregulation of Chronic Hepatitis B Patients", SHANDONG YIYAO - SHANDONG MEDICAL JOURNAL, SHANDONG SHENG WEISHENGTING,, CN, vol. 60, no. 1, 1 January 2020 (2020-01-01), CN , pages 90 - 94, XP093153210, ISSN: 1002-266X, DOI: 10.3969/j.issn.1002-266X.2020.01.025
SCOTT BALSITIS: "Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 13, no. 2, 14 February 2018 (2018-02-14), US , pages e0190058, XP093153221, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0190058
JIAO LIU: " Research Progress of PD-1/PD-L1 Signal Pathway in Immunoregulation of Chronic Hepatitis B Patients", SHANDONG YIYAO - SHANDONG MEDICAL JOURNAL, SHANDONG SHENG WEISHENGTING,, CN, vol. 60, no. 1, 1 January 2020 (2020-01-01), CN , pages 90 - 94, XP093153210, ISSN: 1002-266X, DOI: 10.3969/j.issn.1002-266X.2020.01.025
SCOTT BALSITIS: "Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 13, no. 2, 14 February 2018 (2018-02-14), US , pages e0190058, XP093153221, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0190058
Attorney, Agent or Firm:
CHINA SCIENCE PATENT & TRADEMARK AGENT LTD. (CN)
Download PDF: